Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Production Technology (Mammalian, Non-Mammalian), By Application (Oncology, Blood Disorders), By Product, By Region, And Segment Forecasts, 2022 - 2030

Biosimilar Contract Manufacturing Market Growth & Trends

The global biosimilar contract manufacturing market size is expected to reach USD 25.7 billion by 2030, registering a CAGR of 18.5% during the forecast period, according to a new report by Grand View Research, Inc. Growing demand for low-cost therapeutics and the increasing prevalence of diseases, such as cancer, autoimmune disorders, blood disorders, and other diseases are the major factors driving the industry. In recent years, the approvals for biosimilar drugs have increased. For instance, in August 2022, the U.S. FDA approved Coherus’ drug Cimerli as an interchangeable biosimilar for Lucentis.

This biosimilar is used in treating ophthalmology conditions, such as Diabetic Macular Edema (DME), Macular Edema following Retinal Vein Occlusion (RVO), Neovascular (wet) Age-Related Macular Degeneration (AMD) Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV). A growing number of biosimilar approvals are expected to profit the industry post-pandemic. There has been a rise in the number of biologics losing patents. For instance, biologics, such as Humira, Eylea, Keytruda, Stelara, Revlimid, and Eliquis, are expected to lose patents by 2030. The growing number of biologics losing patents is expected to promote the demand for biosimilars, thus promoting industry growth.

A significant number of small- and medium-sized biopharmaceutical companies lack infrastructure for manufacturing biosimilars. Furthermore, big pharmaceutical companies try to focus on their core competencies, such as research and marketing, owing to which they outsource manufacturing services. Such factors are further expected to promote industry growth to a great extent. Cancer is one of the major causes of death worldwide. The estimates of Cancer Tomorrow state that cancer is expected to affect 30.2 million people by 2040. The rising burden of the disease and the high cost of drugs are expected to promote the demand for low-cost biosimilars. This is likely to improve the manufacturing of cancer biosimilar in the post-pandemic period.

Biosimilar Contract Manufacturing Market Report Highlights

• The mammalian production technology segment dominated the industry in 2021 as the majority of research activities are being carried out using mammalian cell lines
• The recombinant non-glycosylated proteins segment accounted for the largest revenue share in 2021 owing to its effectiveness in treating diseases, such as cancer and diabetes
• The chronic and autoimmune disorders segment held the largest share of the overall revenue in 2021
• The growing burden of autoimmune diseases is one of the key factors driving the growth of this segment
• Asia Pacific is expected to register the fastest CAGR over the forecast period due to the growing aging population and high prevalence of chronic & infectious diseases in the region, thus promoting the demand for cost-effective treatments